RO 462005

Drug Profile

RO 462005

Latest Information Update: 15 Nov 2006

Price : $50

At a glance

  • Originator Roche
  • Class Antihypertensives; Antihypotensives; Small molecules
  • Mechanism of Action Endothelin receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Hypertension

Most Recent Events

  • 15 Nov 2006 Discontinued - Preclinical for Hypertension in Switzerland (unspecified route)
  • 02 Sep 1998 No-Development-Reported for Hypertension in Switzerland (Unknown route)
  • 16 Jul 1998 A study has been added to the pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top